Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply

Maria Fleseriu; Frederic Castinetti; Monica Gadelha; Andrea Giustina; Andre Lacroix; Shlomo Melmed; John Newell-Price; Rosario Pivonello; Martin Reincke; Beverly M. K. Biller; Consensus Diag Management Cushing

Journal Articles LANCET DIABETES & ENDOCRINOLOGY Year : 2022

Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply

, (1, 2, 3) , , , , , , , , ,

1
2
3

Maria Fleseriu

Function : Author

Frederic Castinetti

Function : Author
PersonId : 16755
IdHAL : frederic-castinetti
ORCID : 0000-0002-1808-8800
IdRef : 113296061

Marseille medical genetics - Centre de génétique médicale de Marseille

Institut Marseille Maladies Rares

Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM]

Monica Gadelha

Function : Author

Andrea Giustina

Function : Author

Andre Lacroix

Function : Author

Shlomo Melmed

Function : Author

John Newell-Price

Function : Author

Rosario Pivonello

Function : Author

Martin Reincke

Function : Author

Beverly M. K. Biller

Function : Author

Consensus Diag Management Cushing

Function : Author

Domains

Life Sciences [q-bio] Genetics

Marc Bartoli : Connect in order to contact the contributor

https://hal-amu.archives-ouvertes.fr/hal-03780355

Submitted on : Monday, September 19, 2022-11:39:10 AM

Last modification on : Wednesday, February 8, 2023-5:14:05 PM

Dates and versions

hal-03780355 , version 1 (19-09-2022)

Identifiers

HAL Id : hal-03780355 , version 1

Cite

Maria Fleseriu, Frederic Castinetti, Monica Gadelha, Andrea Giustina, Andre Lacroix, et al.. Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply. LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (6), pp.385-387. ⟨hal-03780355⟩

Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply

Domains

Dates and versions

Identifiers

Cite

Export

Collections

Share